Home » Topics » Regulatory » EMA

EMA
RSS

European CHMP recommends approval of tablet formulation of Noxafil

March 3, 2014

EMA accepts MAA filing for oritavancin

Feb. 28, 2014

EMA accepts tedizolid phosphate MAA for review

Feb. 28, 2014

Orexigen Therapeutics receives European CHMP questions on NB-32 MAA

Feb. 27, 2014

ImmunoCellular Therapeutics receives orphan drug status in Europe for ICT-107 in glioblastoma

Feb. 26, 2014

EMA concludes review of Protelos/Osseor

Feb. 24, 2014

GSK's umeclidinium recommended for E.U. approval in treatment of COPD

Feb. 21, 2014

EMA committee recommends approval of BioMarin's Vimizim for Morquio A syndrome

Feb. 21, 2014

Anoro receives positive CHMP opinion for the treatment of COPD

Feb. 21, 2014

European COMP recommends orphan drug designation for ISIS-TTRRx

Feb. 17, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...